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Abstract: The Clinical Pharmacogenetics Implementation Consortium (CPIC®) establishes evidence-
based guidelines for utilizing pharmacogenetic information for certain priority drugs. Warfarin,
clopidogrel and simvastatin are cardiovascular drugs that carry strong prescribing guidance by
CPIC. The respective pharmacogenes for each of these drugs exhibit considerable variability amongst
different ethnic/ancestral/racial populations. Race and ethnicity are commonly employed as sur-
rogate biomarkers in clinical practice and can be found in many prescribing guidelines. This is
controversial due to the large variability that exists amongst different racial/ethnic groups, lack
of detailed ethnic information and the broad geographic categorization of racial groups. Using
a retrospective analysis of electronic health records (EHR), we sought to determine the degree to
which self-reported race/ethnicity contributed to the probability of adverse drug reactions for these
drugs. All models used individuals self-reporting as White as the comparison group. The majority of
apparent associations between different racial groups and drug toxicity observed in the “race only”
model failed to remain significant when we corrected for covariates. We did observe self-identified
Asian race as a significant predictor (p = 0.016) for warfarin hemorrhagic events in all models. In
addition, patients identifying as either Black/African-American (p = 0.001) or Other/Multiple race
(p = 0.019) had a lower probability of reporting an adverse reaction than White individuals while on
simvastatin even after correcting for other covariates. In both instances where race/ethnicity was
predictive of drug toxicity (i.e., warfarin, simvastatin), the findings are consistent with the known
global variability in the pharmacogenes described in the CPIC guidelines for these medications.
These results confirm that the reliability of using self-identified race/ethnic information extracted
from EHRs as a predictor of adverse drug reactions is likely limited to situations where the genes
influencing drug toxicity display large, distinct ethnogeographic variability.
Keywords: pharmacogenomics; clopidogrel; warfarin; simvastatin; race; ethnicity; toxicity
1. Introduction
While the U.S. Food and Drug Administration has added pharmacogenetic informa-
tion to over 150 drug labels (https://www.fda.gov/drugs/science-and-research-drugs/
table-pharmacogenomic-biomarkers-drug-labeling, accessed on 10 May 2021), the clinical
implementation of this guidance is limited at best. As a result, the Clinical Pharmaco-
genetics Implementation Consortium (CPIC®) was created to establish peer-reviewed,
evidence-based guidelines for utilizing the results from pharmacogenetic (PGx) tests. CPIC
guidelines are conservative and aimed at providing a clinical decision framework for the
utilization of PGx to guide pharmacotherapy for certain “priority” drugs. Among the
prioritization of CPIC recommendations, drug/gene pairs with Level A notation indicate
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that “genetic information should be used to change prescribing of affected drug”. Hence,
drugs with Level A evidence possess CPIC’s strongest prescribing recommendations.
There exists large disparities between various racial/ethnic/ancestral groups for both
cerebrovascular/cardiovascular disease risk as well as response to pharmacotherapeutic
interventions for these conditions [1–5]. Recent work in the field of pharmacogenomics
has increasingly focused on the identification of ethnicity/population-specific variation
in drug metabolizing and drug target genes that can help account for these differences.
For example, individuals identifying as having African ancestry have a higher risk of
developing cardiovascular disease (CVD) than individuals of European-American ancestry
(EA) [1]. African-Americans (AAs) have a higher on-treatment platelet reactivity with
antiplatelet drugs such as clopidogrel, suggesting a pharmacogenetic variation in drug
metabolism [6]. Observations of differential racial or ethnic risk of disease/treatment
failure is not only limited to thrombotic disease. For instance, Asian ancestry confers a
higher risk for intracerebral hemorrhage (ICH) amongst all ethnicities worldwide. In the
US, AAs also carry a greater risk of ICH than individuals of European ancestry [7].
There are three cardiovascular drugs that carry Level A prescribing guidance by CPIC:
warfarin, clopidogrel and simvastatin. Warfarin is an oral anticoagulant that targets Vitamin
K oxidoreductase complex 1 (VKORC1) thereby preventing the carboxylation/activation
of clotting factors. A large amount of research supports variation in CYP2C9 and VKORC1
significantly contributing to both the warfarin dose and incidence of severe toxicity (i.e.,
intracerebral hemorrhage) [8]. Clopidogrel, a prodrug, is an anti-platelet agent that targets
the P2Y12 adenosine receptor. CPIC guidance on clopidogrel focuses on the impact of
CYP2C19 variation and treatment response in patients with acute coronary syndrome
(ACS) undergoing percutaneous coronary intervention (PCI). Simvastatin is an HMG-
CoA reductase inhibitor used for the treatment of hypercholesterolemia. While generally
well-tolerated, simvastatin use has been associated with myalgias, myopathy and, in rare
cases, rhabdomyolysis [9,10]. While the frequency of reported statin-associated myalgias is
no different than placebo [11,12], severe muscle toxicity has been associated with allelic
variation in the SLCO1B1 (OATP1B1) gene [10] which facilitates hepatic uptake of the drug.
The use of race and ethnicity in medicine is controversial due to the large variability
amongst different racial/ethnic groups, lack of detailed ethnic information, the co-existence
of social and environmental determinants of health, and the broad geographic categoriza-
tion of “racial” groups (i.e., Asian, African). Yet, race and ethnicity are still employed as
surrogate biomarkers in clinical practice [13,14] including in many US FDA prescribing
guidelines [15]. For each of the drugs described above, considerable variability amongst
different ethnic/ancestral/racial populations [16–20] exists within their respective phar-
macogenes covered in the CPIC guidelines. Given this variability, and its potential impact
on drug response and toxicity, we sought to determine the degree to which race/ethnicity
contributed to the frequency of adverse drug reactions for these priority drugs. We per-
formed a retrospective analysis of electronic health records (EHR) for these drugs from a
large, diverse medical center in Washington, DC.
2. Materials and Methods
2.1. Subject Recruitment
The study was considered exempt by the George Washington University Institutional
Review Board (GWU IRB #NCR202660). We extracted all data from the GWA query that
was developed to screen for patients at the George Washington University Medical Center
Medical Faculty Associates EHR (Allscripts) using a drug-specific query. We extracted
all data from the patients’ EHR. Inclusion criteria included in the study were >18 years
of age and on at least one of the study drugs during the time period 2016–2020. For
eligible subjects, we collected demographic information data (age, type of insurance if any,
self-reported race and ethnicity), clinical data (BMI) and presence or absence of clinically
significant drug interactions and outcomes (see Appendix A, Table A1).
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2.2. Statistical Analyses
Inference was conducted independently for each of the warfarin, clopidogrel, and
simvastatin patient samples. The warfarin and clopidogrel patient samples featured two
primary endpoints of interest: any hemorrhaging events, and any adverse events (includ-
ing hemorrhaging). The simvastatin sample only featured adverse outcomes, excluding
hemorrhage, as an endpoint. For each sample and endpoint, an initial logistic regression
featuring only race and ethnicity as predictors was fit to determine if there were any unad-
justed differences in risk profiles between racial groups. After the baseline regressions were
fit, a series of logistic regressions were conducted to account for other clinical covariates.
These regressions featured main effect and interaction terms for race and ethnicity, as
well as age, body mass index (BMI), and indicators for diabetes, hypertension, coronary
artery disease, chronic obstructive pulmonary disease, high creatinine levels, high alanine
aminotransferase (ALT) levels, other prescription drug use, alcohol use, and tobacco use. A
series of prespecified tests were then conducted for each of these adjusted regressions to
test for the importance of groupwise race and ethnicity interactions, high ALT values, and
groupwise race and ethnicity effects. Due to missing patient data for the high creatinine
and high ALT indicators, adjusted regressions were performed on ten imputed datasets for
each sample, with imputation being performed through logistic regressions. Due to the
imputation scheme, groupwise statistical tests were conducted using Rubin’s likelihood
ratio test and Rubin’s Wald test, while individual predictors were assessed using Rubin’s
Wald test.
3. Results
After adjusting for multiple entries for patients during the five-year period, we ob-
tained 2139, 4190 and 11,522 records for warfarin, clopidogrel and simvastatin, respectively.
The descriptive statistics for each drug group are provided in Table 1. Similar covariates
were obtained for each population. The primary endpoints for warfarin and clopidogrel
were total number of bleeding events and adverse drug reactions. For simvastatin, we
explored the total number of reported adverse events as our primary clinical endpoint.
This was inclusive of myopathic events which were found to be unrelated to simvastatin
exposure (data not shown). The individual ICD-10 codes and list of clinically significant
drug interactions included in our models are provided in Appendix A, Table A1. Impor-
tantly, we utilized racial/ethnic information exactly as provided in the electronic health
record (EHR) for our analyses. All comparisons in the study were made within each drug
group using the self-identified White population as the reference group for our analyses.
Table 1. Characteristics of study populations.
Variable Warfarin Clopidogrel Simvastatin
N = 2139 4190 11,522
Age (y) 71.5 (15.1) 71.9 (12.3) 69.5 (12.3)
BMI 29.7 (7.7) 29.1 (6.4) 29.6 (6.6)
Male 60.1% 62.4% 50.2%
Female 39.9% 37.6% 49.8%
Race
White/European-
American 47.1% 35.3% 40.0%
Black/African-American 28.8% 36.2% 28.9%
Unknown/Declined Race 13.9% 13.4% 14.0%
Other/Multiple Race 6.4% 9.0% 10.2%
Asian 3.8% 6.2% 7.0%
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Table 1. Cont.
Variable Warfarin Clopidogrel Simvastatin
Diabetes
No 84.5% 68.5% 73.8%
Yes 15.5% 31.6% 26.2%
Hypertension
No 70.1% 51.7% 61.8%
Yes 29.9% 48.3% 38.2%
CAD
No 90.0% 58.7% 95.0%
Yes 10.0% 41.3% 5.1%
COPD
No 96.4% 95.4% 97.9%
Yes 3.6% 4.6% 2.1%
Alcohol
Abuse/Dependence
No 96.4% 96.3% 95.9%
Yes 3.6% 3.7% 4.1%
Tobacco Use
No 97.6% 95.3% 97.1%
Yes 2.4% 4.7% 2.9%
Creatinine (>1 mg/dL)
No 83.2% 75.1% 88.7%
Yes 16.8% 24.9% 11.3%
ALT (>50)
No 96.9% 96.4% 98.8%
Yes 3.1% 3.6% 1.2%
NSAID Use
No 67.2% 82.3% na
Yes 32.8% 17.7% na
Any Drug Interaction
No 89.2% 72.2% 73.8%




No 96.5% 97.2% na
Yes 3.5% 2.8% na
Any Adverse Outcome
No 90.3% 86.7% 99.1%
Yes 9.7% 13.3% 0.9%
Abbreviations: BMI-body mass index; COPD- chronic obstructive pulmonary disease, CAD-coronoary artery
disease, ALT-alanine aminotransferase, NSAID- non-steroidal anti-inflammatory drug.
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3.1. Warfarin
Warfarin has an extremely narrow therapeutic index and exhibits a large degree of het-
erogeneity for both treatment outcome and adverse events [8,21]. Bleeding/hemorrhagic
events associated with suboptimal warfarin dosing are associated with significant mor-
bidity and mortality [19,22,23]. We focused on comparing the frequency of both overall
adverse events and hemorrhagic complications between different racial/ethnic groups
compared to self-identified White patients. Co-variates for the warfarin group included
hypertension (29.9%), diabetes (15.5%), coronary artery disease (CAD, 10%), impaired
hepatic function (alanine aminotransferase (ALT); 3.1%), impaired renal function (crea-
tinine clearance >1 mg/dL; 16.8%) and chronic obstructive pulmonary disease (COPD,
3.6%). Tobacco use and alcohol dependence/abuse was present in 2.4% and 3.6% of the
subjects, respectively. Warfarin, a CYP2C9 substrate, has many potential drug interactions.
Nearly 11% of subjects were prescribed medications with the potential of causing clinically
significant interactions with warfarin. Almost a third of patients were also prescribed an
NSAID according to the EHR (32.8%).
The frequency of patients experiencing any adverse event was significantly higher
(p = 0.014) for individuals identifying as Black/African-American (compared to White race)
in the race-only model (Figure 1A). However, this difference disappeared when correcting
for the covariates (Table 2). In the Asian group (3.8% of the group), the probability of
experiencing any hemorrhagic complication while taking warfarin was significantly higher
than the White group (p = 0.007) (Figure 1B). This risk persisted when correcting for all
covariates (Table 3). Female gender (p = 0.022), diabetes (p = 0.019), coronary artery disease
(p = 0.002), chronic obstructive pulmonary disease (p = 0.015) and concurrent NSAID usage
(p = 0.001) were all marginally associated with a greater risk of warfarin adverse drug
reactions. Hypertension and elevated creatinine levels were strongly associated with both
warfarin adverse events as well as bleeding risk.
Figure 1. Race-only model for warfarin adverse events and bleeding events. Shown is the probability of experiencing any
adverse outcome (A) or bleeding events (B) while taking warfarin based on race only. All comparisons used the White
group as the reference.
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Table 2. Logistic regression model for any warfarin adverse drug reactions relative to
White/European-American patients #.
Estimate SE Statistic p-Value
Intercept −3.388 0.631 −5.370 8.76 × 10−8
Asian 0.283 0.378 0.747 0.455
Black/African-
American −0.019 0.194 −0.097 0.922
Other Race a 0.360 0.324 1.111 0.267
Unknown Race b −0.047 0.298 −0.160 0.873
Hispanic or Latino
Ethnicity −0.226 0.398 −0.566 0.571
Unknown Ethnicity −0.330 0.186 −1.776 0.076
Female 0.369 0.160 2.300 0.022
Age 0.005 0.006 0.787 0.431
BMI −0.009 0.011 −0.863 0.388
Diabetes 0.450 0.191 2.355 0.019
Hypertension 0.847 0.171 4.958 7.68 × 10−7
CAD 0.634 0.207 3.055 0.002
COPD 0.729 0.300 2.425 0.015
Alcohol 0.492 0.369 1.333 0.183
Tobacco 0.547 0.384 1.424 0.155
Creatinine
(>1 mg/dL) 0.793 0.192 4.130 4.43 × 10
−5
NSAID Usage 0.558 0.161 3.460 0.001
Any Drug Interaction 0.135 0.223 0.605 0.545
# Patients self-identifying as White/European were used as the reference group for all comparisons. a Other
race includes aggregates of racial groups with small numbers or those with multiple races/ethnicities indicated.
b Unknown race includes patients who declined to identify with any racial group.
Table 3. Logistic regression model for hemorrhage associated with warfarin use relative to
White/European-American patients #.
Estimate SE Statistic p-Value
Intercept −3.996 0.954 −4.190 2.91 × 10−5
Asian 1.120 0.463 2.421 0.016
Black/African-
American −0.083 0.314 −0.264 0.791
Other Race a 0.778 0.467 1.668 0.096
Unknown Race b 0.337 0.467 0.722 0.471
Female Gender −0.146 0.257 −0.568 0.570
Hispanic or Latino
Ethnicity −0.554 0.649 −0.853 0.394
Unknown Ethnicity −0.591 0.305 −1.937 0.053
Age −0.005 0.009 −0.527 0.598
BMI 0.010 0.016 0.604 0.546
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Table 3. Cont.
Estimate SE Statistic p-Value
Diabetes 0.166 0.300 0.552 0.581
Hypertension 0.989 0.272 3.642 2.77 × 10−4
CAD 0.542 0.322 1.682 0.093
COPD 0.299 0.502 0.596 0.551
Alcohol −0.222 0.739 −0.301 0.764
Tobacco 0.585 0.563 1.039 0.299
Creatinine
(>1 mg/dL) 0.798 0.283 2.820 0.005
NSAID Usage 0.227 0.256 0.886 0.376
Any Drug Interaction −0.030 0.366 −0.082 0.935
# Patients self-identifying as White/European were used as the reference group for all comparisons. a Other
race includes aggregates of racial groups with small numbers or those with multiple races/ethnicities indicated.
b Unknown race includes patients who declined to identify with any racial group.
3.2. Clopidogrel
The study population was mostly Black/African-American (36.2%), followed by 35.3%
of patients reporting as White, 13.4% identifying as Unknown/Declined, 9.0% identifying
as Other/Multiple races and 6.2% identifying as Asian (Table 1). Clinically significant
comorbidities for the clopidogrel population included hypertension (48.3%), coronary
artery disease (CAD, 41.3%), diabetes (31.6%) and elevated creatinine (16.8%). Concurrent
tobacco use and alcohol dependence/abuse was present for 4.7% and 3.7% of the subjects,
respectively. We found that 27.8% of subjects had co-exposures to clinically significant
interacting drugs and 17.7% were prescribed an NSAID.
Similar to warfarin, the most severe adverse outcome to clopidogrel is bleeding/ hem-
orrhage events [20]. In addition, clopidogrel under-dosing has been associated with treat-
ment failure related to CYP2C19 metabolizer status [24,25]. The marginal probabilities of
experiencing any adverse outcome was significantly higher in self-identified Black/African-
American patients (p = 0.088) in the race only model (Figure 2A). Of note, respondents with
an unknown race (p = 0.036) were significantly less likely to report an adverse event. Similar
to warfarin, race was no longer a significant predictor after correcting for the covariates
(Table 4). Factors associated with adverse events on clopidogrel included: hypertension
(p = 0.015), tobacco usage (p = 0.021), elevated serum creatinine (p = 0.0003), NSAID usage
(p = 0.001), concomitant NSAID usage (p = 0.001) and any drug interaction (p = 0.009). The
latter predictor was insignificant when concomitant NSAID use was omitted from the
model. In contrast, female gender (p = 0.006), diabetes (p = 0.014) and age (1.05 × 10−6)
were less likely to report an adverse outcome with clopidogrel (Table 4). We found that
patients reporting as Black/African-American exhibited a greater likelihood of experienc-
ing a bleeding event (Figure 2B) which did not remain predictive when we corrected for
other covariates (Table 5). In this cohort of patients, hypertension (p = 6.24 × 10−5), COPD
(p = 0.022), tobacco use (p = 0.05), and elevated serum creatinine (p = 0.004) were associated
with an increased risk of a bleeding event regardless of race/ethic group (Table 5). While
not the focus of the current investigation, we found no reports of treatment failure (based
on ICD-10 code) in the study population (data not shown).
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Figure 2. Race-only model for clopidogrel adverse events and bleeding events. Shown is the probability of experiencing
any adverse outcome (A) or bleeding events (B) while taking clopidogrel based on race only. All comparisons used the
White group as the reference.
Table 4. Logistic regression model for adverse drug reactions associated with clopidogrel use relative
to White/European-American patients #.
Estimate SE Statistic p-Value
Intercept −0.987 0.441 −2.238 0.025
Asian −0.297 0.234 −1.269 0.204
Black/African-
American 0.016 0.124 0.133 0.894
Other Race a −0.099 0.193 −0.514 0.607
Unknown Race b −0.099 0.185 −0.533 0.594
Hispanic or Latino
Ethnicity 0.023 0.247 0.094 0.925
Unknown Ethnicity −0.134 0.115 −1.168 0.243
Female −0.300 0.110 −2.730 0.006
Age −0.021 0.004 −4.890 1.05 × 10−6
BMI −0.014 0.008 −1.775 0.076
Diabetes −0.275 0.111 −2.466 0.014
Hypertension 0.269 0.111 2.434 0.015
CAD 1.471 0.110 13.407 0.00
COPD 0.314 0.196 1.603 0.109
Alcohol 0.073 0.248 0.296 0.767
Tobacco 0.432 0.188 2.304 0.021
Creatinine
(>1 mg/dL) 0.443 0.119 3.713 0.0003
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Table 4. Cont.
Estimate SE Statistic p-Value
NSAID Usage 0.395 0.117 3.389 0.001
Any Drug Interactions 0.438 0.167 2.622 0.009
# Patients self-identifying as White/European were used as the reference group for all comparisons. a Other
race includes aggregates of racial groups with small numbers or those with multiple races/ethnicities indicated.
b Unknown race includes patients who declined to identify with any racial group.
Table 5. Logistic regression model for hemorrhage on clopidogrel relative to White/European-
American patients #.
Estimate SE Statistic p-Value
Intercept −3.936 0.898 −4.382 1.21 × 10−5
Asian −0.768 0.612 −1.255 0.209
Black/African-
American 0.185 0.239 0.777 0.437
Other Race a −0.767 0.519 −1.478 0.140
Unknown Race b −0.089 0.412 −0.215 0.830
Female −0.228 0.210 −1.086 0.278
Hispanic/Latino
Ethnicity 0.438 0.484 0.905 0.366
Unknown Ethnicity −0.314 0.235 −1.336 0.182
Age −0.006 0.009 −0.707 0.480
BMI −0.011 0.015 −0.721 0.471
Diabetes −0.091 0.207 −0.439 0.661
Hypertension 0.998 0.249 4.008 6.24 × 10−5
CAD 0.391 0.204 1.916 0.055
COPD 0.687 0.299 2.297 0.022
Alcohol −0.117 0.491 −0.238 0.812
Tobacco 0.589 0.300 1.964 0.050
Creatinine (>1
mg/dL) 0.601 0.206 2.916 0.004
NSAID Usage 0.522 0.209 2.504 0.012
Any Drug Interaction 0.930 0.261 3.561 0.0004
# Patients self-identifying as White/European were used as the reference group for all comparisons. a Other
race includes aggregates of racial groups with small numbers or those with multiple races/ethnicities indicated.
b Unknown race includes patients who declined to identify with any racial group.
3.3. Simvastatin
Given the broad indication of statins for the treatment of dyslipidemia, the great-
est number of subjects (n = 11,522) were present in the simvastatin group. The popu-
lation consisted of White (40.0%), Black/African-American (28.9%), Asian (7.0%), Un-
known/Declined (14.0%) and Other/Multiple race (10.2%). (Table 1) The largest comor-
bidity for the simvastatin group was hypertension (38.2%). Other comorbid conditions
included diabetes (26.2%), coronary artery disease (5.1%), elevated creatinine (11.3%) and
alcohol use/dependence (4.1%). We found that 27.8% of subjects had been prescribed
clinically significant interacting drugs.
The major adverse event for simvastatin intolerance is clinically significant myopathy
and, in rare cases, rhabdomyolysis [9,10]. The former has been determined to be no greater
than a placebo effect in the absence of elevated creatinine kinase levels [9,12]. However,
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either myopathy and/or rhabdomyolysis, in the presence of elevated enzyme levels, has
been determined to be related to pharmacogenetic variation in the SLOC1B1 gene [10].
When considering race alone, the probability of experiencing any adverse outcome while
taking simvastatin was the same across all racial/ethnic groups (Figure 3). However, we
found that being either of Black/African-American race (p = 0.001) or of Other/Multiple
race (i.e., p = 0.019) was associated with a lower probability of reporting an adverse reaction
while on simvastatin (Table 6) when correcting for all covariates. Furthermore, the only
covariates that were significantly associated with an increased probability of adverse
reactions were lower age (p = 0.00004) and having comorbid hypertension (p = 0.00003).
Figure 3. Race-only model for simvastatin adverse events. Shown is the probability of experiencing
any adverse outcome while taking simvastatin based on race only. All comparisons used the White
group as the reference.
Table 6. Logistic regression model for any simvastatin adverse drug reactions relative to
White/European-American patients #.
Estimate SE Statistic p-Value
Intercept −2.761 0.774 −3.568 0.0004
Asian −0.757 0.477 −1.586 0.113
Black/African-
American −0.915 0.265 −3.458 0.001
Other Race a −0.976 0.416 −2.348 0.019
Unknown Race b −0.547 0.364 −1.503 0.133
Female 0.054 0.203 0.267 0.789
Age −0.034 0.008 −4.128 0.00004
BMI 0.008 0.014 0.560 0.576
Diabetes 0.144 0.230 0.625 0.532
Hypertension 0.937 0.224 4.192 0.00003
CAD 0.275 0.404 0.682 0.495
COPD −0.905 1.012 −0.894 0.371
Alcohol −0.458 0.592 −0.774 0.439
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Table 6. Cont.
Estimate SE Statistic p-Value
Tobacco −0.503 0.721 −0.698 0.485
Creatinine (>1
mg/dL) 0.524 0.282 1.860 0.063
Any Drug Interaction 0.011 0.230 0.047 0.962
# Patients self-identifying as White/European were used as the reference group for all comparisons. a Other
race includes aggregates of racial groups with small numbers or those with multiple races/ethnicities indicated.
b Unknown race includes patients who declined to identify with any racial group.
4. Discussion
Heterogeneity in drug response is a common issue in all areas of medicine. Although
identification of factors accounting for this variability is far from complete, key pharmaco-
genetic factors that influence their efficacy and/or toxicity have been identified for many
drugs. For those factors related to genetic variation, CPIC was established to provide
evidence-based guidance to practitioners for certain drug:gene pairs (https://cpicpgx.org,
accessed on 10 April 2021). Extensive genetic variability exists within the human pop-
ulation for most, if not all, of the pharmacogenes covered in the CPIC guidelines. This
variability has in part contributed to the use of race and ethnicity in clinical prescribing
guidelines [14]. Here, we have examined the degree to which self-identified race may con-
tribute to the probability patients will experience adverse events with three cardiovascular
drugs carrying the strongest prescribing recommendations by CPIC. The results suggest
that apparent associations between race and adverse events is highly drug-specific and
is oftentimes superseded by other clinical and environmental factors (i.e., clopidogrel).
However, in a few instances self-reported race appears to be a significant predictor of
drug toxicity in lieu of other covariates (i.e., warfarin bleeding risk in Asians and lower
simvastatin adverse events in AA). In these situations, the associations are consistent with
known heterogeneity for the relevant pharmacogenes covered in the CPIC guidelines.
The probability of experiencing any adverse drug reaction with warfarin was not
associated with a specific race/ethnic group when corrected for comorbidities except in
self-identified Asian patients. Consequently, the widespread use of race for the purpose of
predicting adverse reactions to warfarin is not warranted based on our study. Predictably,
we found that the known risk factors for warfarin toxicity (i.e., hypertension, CAD, COPD,
renal impairment, and NSAID usage) [23], in addition to female gender, were significant
predictors of warfarin adverse outcomes (Table 2). Diabetes (Type I or II) diagnosis was also
associated with an increased probability of experiencing any adverse event while taking
warfarin (Table 2). This is potentially related to either the significant pharmacokinetic
interactions between warfarin and some antidiabetes drugs [26] and/or other comorbidities
(i.e., hypertension) commonly present in diabetic patients. When we focused on the
probability of experiencing any bleeding events while taking warfarin, we observed that
hypertension and renal impairment both increased probability (Table 3) which is consistent
with other findings [23]. The likelihood of having a bleeding event on warfarin was
significantly higher in self-identified Asian individuals in both the race-only and full
regression models (Figure 2, Table 3). A possible explanation for this finding might be
related to the higher frequency of carriers of the VKORC1 haplotypes which confer a
low-dose warfarin phenotype in Asian populations [17,27] potentially increasing the risk
of warfarin toxicity [19,28]. Although there is a large degree of ethnogeographic variation
amongst different Asian populations [27], there is an overall greater number of “low
dose” VKORC1 genotypes in Asians compared to other populations [29]. For example, the
frequency of the −1639 CC/CT (rs9923231) and 1173 GG/GT (rs9934438) alleles, which
have lower warfarin dose requirements, are much higher in the Chinese vs. Caucasian
populations [29]. Hence, apparent associations between self-identified Asian race and
warfarin bleeding risk are plausible and consistent with the known pharmacogenetics of
this drug.
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Both the U.S. FDA [30] and CPIC [31] warn of therapeutic failure of clopidogrel for pre-
venting thrombotic events in individuals who are CYP219 poor metabolizers. There is con-
siderable worldwide variability within the CYP219 gene suggesting that certain ethnic or ge-
ographically distinct populations may potentially have high on-treatment platelet reactivity
with this drug [32,33] or potentially greater risk of adverse events [33]. Similar to warfarin,
we did not find that race was associated with any adverse events (Figure 2A; Black/African-
American) or bleeding events (Figure 2B; Black/African-American, Other/Multiple race)
while taking clopidogrel when corrected for covariates. (Tables 4 and 5). Given that many
clinical covariates already implicated in predicting clopidogrel response [32] were signifi-
cantly predictive of both clopidogrel adverse events (Table 4) and bleeding events (Table 5),
any apparent associations between race and drug toxicity are better explained by these
factors in this study population. Lastly, the primary clinical endpoints of this study focused
on adverse events and not treatment failure (i.e., thrombotic events). It is likely that race
and ethnicity are not surrogates for any genetic factors that influence the likelihood of
experiencing adverse events while taking clopidogrel.
While all statins carry a small risk of myopathy and elevations in creatinine kinase and
transaminase levels, simvastatin still has a relatively favorable safety profile [9], which is
consistent with the low percentage of adverse events (0.9%) observed in this investigation
(Table 6). In contrast to both warfarin and clopidogrel, the race-only model for simvastatin
failed to yield any associations with adverse events (Figure 3). However, patients identify-
ing as Black/African-American or of Other/Multiple race were significantly less likely to
report an adverse event (Table 6) compared to self-reported White individuals when con-
sidering all other covariates. To the best of our knowledge, this is the first study to report
such an association. Given the relatively small number of adverse events, these results are
somewhat surprising and likely benefited from the relatively large sample size (n = 11,522).
The hepatic uptake of simvastatin is mediated by the organic anionic transporter SLCO1B1
and associations between lower activity SLCO1B1 allelic variants and simvastatin my-
opathy has been observed [34]. Consequently, CPIC recommends either dose-reduction
or switching to an alternative statin (i.e., pravastatin, rosuvastatin) for patients carrying
decreased function SLCO1B1 alleles [10]. Interestingly, the African population has a lower
frequency of SLCO1B1 alleles conferring lower transporter activity [16,34]. For example,
the SLCO1B1*15 allele occurs in approximately 2.9% of Africans and 13% of Europeans and
the SLCO1B1*5 allele (2.8% of Europeans) has not been detected in African populations [35].
Moreover, individuals of European ancestry have a greater area under the curve (AUC)
and slower clearance for pravastatin than African-Americans [36]. While we have no
information on SLCO1B1 genotype in our study population, it is possible that individuals
identifying as Black/African-American in this study were less likely to carry decreased
functioning SLCO1B1 alleles relative to the “White” patients taking simvastatin. However,
it is equally possible that environmental/nongenetic factors can account for this discrep-
ancy in adverse events. For example, Black/African-American and/or Other/Multiple race
patients could have been less likely to report adverse reactions or seek medical care while
taking simvastatin. Indeed, racial disparities in adverse drug reactions have been observed
in other studies [5,28]. As a result, these findings require further detailed investigation.
This study has several strengths including its diverse study population (>50% of
patients identified as non-White) and the relatively large sample size of each drug group.
However, there are several limitations to the study that warrant discussion. First and
foremost, we have relied on EHRs for all of our analyses. These are inherently incomplete
and oftentimes lack detailed information. We also utilized ICD-10 codes for our endpoints,
and many covariates, which are frequently nonspecific and somewhat subjective. In
addition, many studies have highlighted the limited usefulness of social constructs such
as race and ethnicity data in retrospective studies. Indeed, the self-reported racial and
ethnic information present in the EHR lacks granular information on specific racial and
ethnic subgroups that would have strengthened this investigation and the validity of its
conclusions. Along these same lines, we were unable to obtain genotypic information on
J. Pers. Med. 2021, 11, 1226 13 of 16
the relevant pharmacogenes for each drug which would have allowed analysis to include
genetic predisposition in addition to race/ethnicity. Similarly, we lacked DNA/data on
ancestry informative markers as a more accurate index of self-reported race and ethnicity
which would have more accurately characterized the ethnogeographic composition of our
study population. Consequently, the broad categorization of race/ethnicity in the EHR is
somewhat reflected in the large variability of probabilities observed in the race-only models.
Taken together, any of the observed correlations between self-reported race/ethnicity and
adverse treatment outcome may not be applicable to other populations in more rural areas
and/or datasets that contain more detailed ethnoracial information.
The use of race and ethnicity in clinical decision-making and in U.S. FDA package
inserts are controversial given that they do not adequately reflect subgroup populations and
are confounded by social determinants of health and health inequities. This being said, both
terms are often used as surrogate genetic markers of disease risk and therapeutic outcome.
This work highlights the somewhat limited biological value of utilizing race and ethnicity
as predictors of drug toxicity. As we have shown, apparent associations between adverse
drug outcomes and race can often be explained by other clinical (i.e., co-morbidities)
and environmental (i.e., drug interactions, tobacco usage) factors. In certain situations
where the variability of pharmacogenes is geographically diverse, race/ethnicity may be
informative variables to include along with other factors commonly used in therapeutic
decision-making (i.e., liver/kidney function, BMI) for predicting ADRs. While interesting,
the results of this study require further prospective analyses in large, diverse populations
accompanied by biological samples that will help yield genetic factors that can potentially
account for the findings observed in this investigation.
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Appendix A
Table A1. List of International Classification of Diseases, 10th Revision (ICD-10) codes for co-variates, drug interactions and clinical endpoints.










Warfarin I48, G45, I63,I82, I26 E10, E11
I10, I11, I12,












D69.9, I61, I62, K92.2,
K92.0, R04.9, R04.8,
K92.1, R58, D69, I31.2,





K75.9, I96, I70.26, I73,
A48.0,L88
Clopidogrel I25, I70, I73,I63, G45 E10, E11
I10, I11. I12,












D69.9, I61, I62, K92.2,
K92.0, R04.9, R04.8,
K92.1, R58, D69, I31.2,
I60, I85.0, K25.0, K26.0,
K27.0, K52.1, K62.5,
K66.1, M25.0, N92.4,







Simvastatin E78, I25, I70,I73 E10, E11
I10, I11, I12,









T46.6, K85.3, T46, T78,





Abbreviations: HTN—hypertension, CAD—coronary artery disease, COPD—chronic obstructive pulmonary disease. A code marked with an asterisk (*) represents the symptoms or manifestations of a disease.
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